A Unique Anti-Cancer 3-Styrylchromone Suppresses Inflammatory Response via HMGB1-RAGE Signaling
High mobility group box 1 (HMGB1)-receptor for advanced glycation endo-products (RAGE) axis serves as a key player in linking inflammation and carcinogenesis. Recently, papaverine was revealed to suppress the HMGB1-RAGE inflammatory signaling pathway and cancer cell proliferation. Therefore, a dual...
Main Authors: | Hideaki Abe, Miwa Okazawa, Takahiro Oyama, Hiroaki Yamazaki, Atsushi Yoshimori, Takanori Kamiya, Mitsutoshi Tsukimoto, Koichi Takao, Yoshiaki Sugita, Hiroshi Sakagami, Takehiko Abe, Sei-ichi Tanuma |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Medicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2305-6320/8/4/17 |
Similar Items
-
Role and Mechanisms of RAGE-Ligand Complexes and RAGE-Inhibitors in Cancer Progression
by: Ali H. El-Far, et al.
Published: (2020-05-01) -
Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation
by: Huan Yang, et al.
Published: (2019-04-01) -
Mechanism of HMGB1–RAGE in Kawasaki disease with coronary artery injury
by: Biying Qian, et al.
Published: (2020-03-01) -
Increased dermal expression of chromatin-associated protein HMGB1 and concomitant T-cell expression of the DNA RAGE in patients with psoriasis vulgaris
by: Strohbuecker L, et al.
Published: (2019-02-01) -
Impact of HMGB1, RAGE, and TLR4 in Alzheimer’s Disease (AD): From Risk Factors to Therapeutic Targeting
by: Yam Nath Paudel, et al.
Published: (2020-02-01)